S100A9-CXCL12 signaling activation could enhance cancer progression and trigger the expansion and accumulation of myeloid-derived suppressor cells (MDSCs), producing a tumor-permissive microenvironment and endowing resistance to ICB in BRCA1-mutant breast cancers (21). Here, S100A9 is linked to neoplasm.